A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One TNF Inhibitor
Latest Information Update: 02 Jan 2024
At a glance
- Drugs Tofacitinib (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms OPAL-BEYOND
- Sponsors Pfizer
- 15 Nov 2023 Results of pooled post hoc analysis data from (NCT01877668 and NCT01882439) assessing variations by identifying pt groups with distinct disease activity trajectories; comparisons of associated baseline (BL) variables across groups were used to describe clinical phenotypes in pts with PsA treated with tofacitinib were presented at the ACR Convergence 2023.
- 22 Aug 2023 Results of pooled post hoc analysis data from (NCT01877668/NCT01882439) tofacitinib efficacy on enthesitis by baseline location and severity, and impact on disease activity and patient-reported outcomes (PROs), in patients with PsA published in the Arthritis Research and Therapy
- 03 Jun 2023 Results of pooled data from (NCT01877668/NCT01882439/NCT03486457/NCT01976364) assessing ong-term safety/efficacy of tofacitinib in TNFi-inadequate responder (IR) and biologic disease-modifying antirheumatic drug (bDMARD)-naive PsA pts presented at the 24th Annual Congress of the European League Against Rheumatism